128 related articles for article (PubMed ID: 28267457)
21. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.
Christensen A; Juhl K; Persson M; Charabi BW; Mortensen J; Kiss K; Lelkaitis G; Rubek N; von Buchwald C; Kjær A
Oncotarget; 2017 Feb; 8(9):15407-15419. PubMed ID: 28039488
[TBL] [Abstract][Full Text] [Related]
22. Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.
Leth JM; Newcombe EA; Grønnemose AL; Jørgensen JT; Qvist K; Clausen AS; Knudsen LBS; Kjaer A; Kragelund BB; Jørgensen TJD; Ploug M
Sci Rep; 2023 Oct; 13(1):17248. PubMed ID: 37821532
[TBL] [Abstract][Full Text] [Related]
23. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
24. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin.
Sonni I; Baratto L; Iagaru A
PET Clin; 2017 Apr; 12(2):159-171. PubMed ID: 28267450
[TBL] [Abstract][Full Text] [Related]
25. Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations.
Wacker A; Bauder-Wüst U; Schäfer M; Schmidt J; Remde Y; Stadlbauer S; Eder M; Liolios C; Kopka K
J Labelled Comp Radiopharm; 2019 Jun; 62(8):483-494. PubMed ID: 30970388
[TBL] [Abstract][Full Text] [Related]
26. Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.
Ploug M
Theranostics; 2013; 3(7):467-76. PubMed ID: 23843894
[TBL] [Abstract][Full Text] [Related]
27. A novel urokinase plasminogen activator receptor-targeted peptide-based probe for in-vivo molecular imaging of glioblastoma.
Han Y; Tu L; Zhang Y; Xu L; Sun Z
Nucl Med Commun; 2023 Feb; 44(2):142-149. PubMed ID: 36630218
[TBL] [Abstract][Full Text] [Related]
28. From Bench to Bed: New Gastrin-Releasing Peptide Receptor-Directed Radioligands and Their Use in Prostate Cancer.
Maina T; Nock BA
PET Clin; 2017 Apr; 12(2):205-217. PubMed ID: 28267454
[TBL] [Abstract][Full Text] [Related]
29. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.
LeBeau AM; Sevillano N; King ML; Duriseti S; Murphy ST; Craik CS; Murphy LL; VanBrocklin HF
Theranostics; 2014; 4(3):267-79. PubMed ID: 24505235
[TBL] [Abstract][Full Text] [Related]
30. Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14).
Fournier P; Dumulon-Perreault V; Ait-Mohand S; Tremblay S; Bénard F; Lecomte R; Guérin B
Bioconjug Chem; 2012 Aug; 23(8):1687-93. PubMed ID: 22770480
[TBL] [Abstract][Full Text] [Related]
31. Clinical indications for Gallium-68 positron emission tomography imaging.
Khan MU; Khan S; El-Refaie S; Win Z; Rubello D; Al-Nahhas A
Eur J Surg Oncol; 2009 Jun; 35(6):561-7. PubMed ID: 19201567
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
33. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
Abdalla MO; Karna P; Sajja HK; Mao H; Yates C; Turner T; Aneja R
J Control Release; 2011 Feb; 149(3):314-22. PubMed ID: 21047537
[TBL] [Abstract][Full Text] [Related]
34. Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients.
Risør LM; Binderup T; Fosbøl MØ; Andersen KF; Loft A; Friborg J; Kjaer A
Sci Rep; 2022 Nov; 12(1):19126. PubMed ID: 36352036
[TBL] [Abstract][Full Text] [Related]
35. Molecular Imaging and Precision Medicine in Prostate Cancer.
Ceci F; Fiorentino M; Castellucci P; Fanti S
PET Clin; 2017 Jan; 12(1):83-92. PubMed ID: 27863569
[TBL] [Abstract][Full Text] [Related]
36. PET/Computed Tomography for Radiation Therapy Planning of Prostate Cancer.
Kairemo KJ
PET Clin; 2017 Apr; 12(2):257-267. PubMed ID: 28267458
[TBL] [Abstract][Full Text] [Related]
37. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
[TBL] [Abstract][Full Text] [Related]
38. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
Cozzi PJ; Wang J; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y
Hum Pathol; 2006 Nov; 37(11):1442-51. PubMed ID: 16949925
[TBL] [Abstract][Full Text] [Related]
40. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
